Cargando…

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies

OBJECTIVES: Lipid profiles are altered by active disease in patients with rheumatoid arthritis (RA) and may be further modified by treatment with Janus kinase inhibitors and other disease-modifying antirheumatic drugs. METHODS: Lipid data were analysed from phase II and III studies of 4 mg (n=997) a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Peter C, Kremer, Joel M, Emery, Paul, Zuckerman, Steven H, Ruotolo, Giacomo, Zhong, Jinglin, Chen, Lei, Witt, Sarah, Saifan, Chadi, Kurzawa, Monika, Otvos, James D, Connelly, Margery A, Macias, William L, Schlichting, Douglas E, Rooney, Terence P, de Bono, Stephanie, McInnes, Iain B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029633/ https://www.ncbi.nlm.nih.gov/pubmed/29463520 http://dx.doi.org/10.1136/annrheumdis-2017-212461

Ejemplares similares

Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2018)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis
por: Zhang, Xin, et al.
Publicado: (2017)

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
por: McInnes, Iain B., et al.
Publicado: (2019)

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2020)

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2020)

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
por: Dougados, Maxime, et al.
Publicado: (2017)

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2017)

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
por: Genovese, Mark C, et al.
Publicado: (2018)

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
por: Smolen, Josef S, et al.
Publicado: (2017)

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: van der Heijde, Desirée, et al.
Publicado: (2018)

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
por: Fleischmann, Roy, et al.
Publicado: (2017)

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
por: Keystone, Edward C, et al.
Publicado: (2017)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
por: Keystone, Edward C, et al.
Publicado: (2015)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)
por: Ramanan, Athimalaipet V., et al.
Publicado: (2021)

Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib
por: Pope, Janet E., et al.
Publicado: (2021)

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
por: Kay, Jonathan, et al.
Publicado: (2020)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
por: Kremer, Joel M, et al.
Publicado: (2018)

Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes
por: Dobosh, Brian, et al.
Publicado: (2022)

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
por: Schiff, Michael, et al.
Publicado: (2017)

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
por: Stebbing, Justin, et al.
Publicado: (2020)

Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial
por: Dörner, Thomas, et al.
Publicado: (2022)

Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?
por: McCarey, David W, et al.
Publicado: (2005)

Porous silicon-based nanostructured microparticles as degradable supports for solid-phase synthesis and release of oligonucleotides
por: McInnes, Steven J P, et al.
Publicado: (2012)

High-throughput nuclear magnetic resonance measurement of citrate in serum and plasma in the clinical laboratory
por: Garcia, Erwin, et al.
Publicado: (2021)

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
por: Tuttle, Katherine R, et al.
Publicado: (2018)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

Experimental phasing of serial femtosecond crystallography data
por: Schlichting, Ilme
Publicado: (2017)

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
por: Taylor, Peter C., et al.
Publicado: (2019)

Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
por: Combe, Bernard, et al.
Publicado: (2019)

GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk
por: Connelly, Margery A., et al.
Publicado: (2017)

Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies
por: Buhl, Timo, et al.
Publicado: (2021)

Relative Impact of Pain and Disease Activity on Improvements in Fatigue: Results From 2 Baricitinib Phase 3 Clinical Trials
por: Fautrel, Bruno, et al.
Publicado: (2023)

Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies
por: Taylor, Peter C., et al.
Publicado: (2023)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d7k761u4om0lv3ituu9sq8rg6d